A Phase One, Open Label, Multi-Dose Study To Evaluate The Safety, Tolerability, And Biologic Effects Of Three Doses Of Iw001 In Patients With Idiopathic Pulmonary Fibrosis (ipf)

被引：0
|
作者：
Rothhaar, K. [1 ]
Chew, T. [1 ]
Frye, S. [1 ]
Klemsz, M. [2 ]
Lange, W. [1 ]
Wilkes, D. S. [2 ]
机构：
[1] ImmuneWorks Inc, Indianapolis, IN USA
[2] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2013年 / 187卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A5709
引用
收藏
页数：1
相关论文
共 44 条
  • [1] A Phase One, Open Label, Multi-Dose Study To Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients with Idiopathic Pulmonary Fibrosis (IPF)
    Rothhaar, K.
    Chew, T.
    Frye, S.
    Klemsz, M.
    Lange, W.
    Wilkes, D. S.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2013, 32 (04): : S168 - S168
  • [2] An Open-Label, Phase Ii Study (pipf-002) Of The Safety Of Pirfenidone In Patients With Idiopathic Pulmonary Fibrosis (ipf)
    Gotfried, M. H.
    Girod, C. E.
    Antin-Ozerkis, D. E.
    Odueyungbo, A.
    Hormel, P.
    Strombom, I.
    Stauffer, J. L.
    Kirchgassler, K. -U.
    Padilla, M. L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [3] An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002)
    Gotfried M.H.
    Girod C.E.
    Antin-Ozerkis D.
    Burgess T.
    Strombom I.
    Stauffer J.L.
    Kirchgaessler K.-U.
    Padilla M.L.
    Pulmonary Therapy, 2018, 4 (1) : 59 - 71
  • [4] An open-label phase I study to evaluate the safety, tolerability and preliminary efficacy of YY001 in patients with advanced solid tumors
    Xue, Liqiong
    Tang, Wenbo
    Zhou, Huan
    Liu, Mulin
    Liu, Yuanyuan
    Wang, Jinhua
    Chen, Jianfeng
    Liu, Mingyao
    Guo, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension
    Simon, Marc A.
    Hanrott, Kate
    Budd, David C.
    Torres, Fernando
    Gruenig, Ekkehard
    Escribano-Subias, Pilar
    Meseguer, Manuel L.
    Halank, Michael
    Opitz, Christian
    Hall, David A.
    Hewens, Deborah
    Powley, William M.
    Siederer, Sarah
    Bayliffe, Andrew
    Lazaar, Aili L.
    Cahn, Anthony
    Rosenkranz, Stephan
    PULMONARY CIRCULATION, 2022, 12 (01)
  • [6] Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON
    Crestani, Bruno
    Huggins, John T.
    Kaye, Mitchell
    Costabel, Ulrich
    Glaspole, Ian
    Ogura, Takashi
    Song, Jin Woo
    Stansen, Wibke
    Quaresma, Manuel
    Stowasser, Susanne
    Kreuter, Michael
    LANCET RESPIRATORY MEDICINE, 2019, 7 (01): : 60 - 68
  • [7] Protocol for a Phase 1, Open-Label, Multiple-Center, Dose-Escalation Study to Evaluate the Safety and Tolerability of ADR-001 in the Treatment of Immunoglobulin A Nephropathy
    Tanaka, Akihito
    Furuhashi, Kazuhiro
    Fujieda, Kumiko
    Maeda, Kayaho
    Saito, Shoji
    Mimura, Tetsushi
    Saka, Yosuke
    Naruse, Tomohiko
    Ishimoto, Takuji
    Kosugi, Tomoki
    Kinoshita, Fumie
    Kuwatsuka, Yachiyo
    Shimizu, Shinobu
    Nakai, Yasuhiro
    Maruyama, Shoichi
    FRONTIERS IN MEDICINE, 2022, 9
  • [8] Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis
    Khouri, Jack
    Anwer, Faiz
    Samaras, Christy J.
    Garcia, Alex V. Mejia
    Koc, Omer N.
    Faiman, Beth M.
    Hamilton, Kimberly
    Mathur, Saveta
    Scott, Cynthia
    Stefunek, Kathleen
    Sgobbo, Josephine
    Fada, Sherry
    Lewis, Brittany
    Shepherd, Kelly
    Ahmad, Naqib
    Knebusch, Madeleine
    Sobolov, Susan B.
    Jobes, Janet
    Daniel, Eileen
    Spector, Michael
    Valent, Jason
    BLOOD, 2020, 136
  • [9] A multicenter open-label phase I/II study to assess the safety, tolerability, and efficacy of three dose levels of TuNEX in patients with rheumatoid arthritis
    Chen, Der-Yuan
    Lai, Ning-Sheng
    Lu, Ling-Ying
    Chou, Hsiu-Cheng
    Chen, Yi-Hsing
    Hsieh, Tsu-Yi
    Chen, Yi-Ming
    Lan, Joung-Liang
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2011, 74 (12) : 544 - 551
  • [10] Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study
    Raghu, Ganesh
    Hamblin, Mark J.
    Brown, A. Whitney
    Golden, Jeffrey A.
    Ho, Lawrence A.
    Wijsenbeek, Marlies S.
    Vasakova, Martina
    Pesci, Alberto
    Antin-Ozerkis, Danielle E.
    Meyer, Keith C.
    Kreuter, Michael
    Burgess, Tracy
    Kamath, Nikhil
    Donaldson, Francis
    Richeldi, Luca
    RESPIRATORY RESEARCH, 2022, 23 (01)
12345